New hope for kids with rare muscle-wasting disease as drug combo moves to next phase
NCT ID NCT03845712
First seen Feb 28, 2026 · Last updated May 24, 2026 · Updated 5 times
Summary
This study tests two oral medications, doxecitine and doxribtimine, in 47 people with thymidine kinase 2 (TK2) deficiency, a rare genetic disorder that causes severe muscle weakness. Participants are already receiving similar treatment and will continue under close monitoring. The main goal is to check safety and see if the drugs help improve muscle function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMIDINE KINASE 2 DEFICIENCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tk0102 1005
New York, New York, 10032, United States
-
Tk0102 3031
Madrid, Spain
-
Tk0102 3101
Seville, Spain
-
Tk0102 3102
Barcelona, Spain
-
Tk0102 3121
Esplugues de Llobregat, Spain
-
Tk0102 4037
Nehariya, Israel
-
Tk0102 4038
Haifa, Israel
-
Tk0102 4039
Holon, Israel
Conditions
Explore the condition pages connected to this study.